Reduction in HIF-1α and expression of angiogenic factors (FGF2, PDGF-AA, CYR61, and VEGF) and subsequently intratumor hypoxia is due to the ability of Infigratinib/Bevacizumab to increase tumor oxygen supply via Infigratinib-induced vascular normalization of tumor blood vessels. The gene discussed is VEGFA; the disease is neoplasm.